STTK · Shattuck Labs, Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $1M | $1M | $5.72M | $1.66M | $652K | $30.02M | $9.93M | $9.89M | |
| $36.3M | $35.27M | $67.21M | $74.31M | $82.9M | $56.56M | $37.48M | $29.22M | |
| $17.36M | $17.24M | $19.08M | $19.3M | $21.08M | $18.72M | $9.38M | $5.74M | |
| — | $3.7M | $3.8M | $4M | $3.1M | $1.4M | $600K | $500K | |
| $53.66M | $52.51M | $86.29M | $93.61M | $103.98M | $75.29M | $46.87M | $34.95M | |
| -$52.66M | -$51.51M | -$80.57M | -$91.96M | -$103.33M | -$45.27M | -$36.93M | -$25.07M | |
| — | -5150.8% | -1408.27% | -5549.61% | -15848.01% | -150.81% | -371.76% | -253.53% | |
| — | -$47.81M | -$76.77M | -$87.96M | -$100.23M | -$43.87M | -$36.33M | -$24.57M | |
| — | $2.7M | $5.17M | $4.67M | $1.59M | $625K | $549K | $1.18M | |
| $2.79M | $2.7M | $5.16M | $4.66M | $1.38M | $295K | $328K | $1.09M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$49.87M | -$48.81M | -$75.41M | -$87.3M | -$101.95M | -$44.97M | -$36.6M | -$23.98M | |
| — | -4880.9% | -1318.13% | -5268.44% | -15635.74% | -149.83% | -368.46% | -242.56% | |
| -$49.87M | -$48.81M | -$75.41M | -$86.42M | -$102.26M | -$45.47M | -$36.72M | -$23.93M | |
| USD/shares | — | -$0.70 | -$1.49 | -$2.05 | -$2.41 | -$1.07 | -$2.36 | — |
| USD/shares | — | -$0.70 | -$1.49 | -$2.05 | -$2.41 | -$1.07 | -$2.36 | — |
| shares | — | 69.58M | 50.76M | 42.6M | 42.38M | 42.03M | 15.51M | 7.56M |
| shares | — | 69.58M | 50.76M | 42.6M | 42.38M | 42.03M | 15.51M | 7.56M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 305 similar-size Biotechnology companies (of 520 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $1,000,000 | $5,721,000 | $1,657,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| License | $1,000,000 | $0 |
| Collaboration Revenue | $0 | $5,721,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$51,508,000 | -$80,567,000 | -$91,957,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -5150.8% | -1408.3% | -5549.6% |